stockrow
Saturday 7 November 2026
Export LIANY’s income statement to Excel — free account
LianBio Sponsored ADR
LIANY Healthcare Biotechnology
0.04
0.00
0.00%
Follow LIANY
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | — | — | — | (24) | (140) | (196) | (111) | 311 | 2 | 5 | n/m | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (24) | (140) | (196) | (110) | 311 | 2 | 5 | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.22) | (11.58) | (5.71) | (1.02) | 2.89 | 0.02 | 0.04 | n/m | ||||||
| Cash flow | — | — | — | (0.11) | (8.14) | (4.77) | (0.92) | 2.40 | 0.03 | 0.05 | n/m | ||||||
| Capex | — | — | — | 0.00 | (0.07) | (0.03) | (0.02) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.11) | (8.22) | (4.79) | (0.94) | 2.40 | 0.03 | 0.05 | n/m | ||||||
| Book value | — | — | — | 0.36 | (8.14) | 11.26 | 2.72 | 5.39 | 0.58 | 0.19 | (10.3%) | ||||||
| Shares, m | — | — | — | 108 | 12 | 34 | 108 | 108 | 108 | 109 | +0.1% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (12) | (98) | (164) | (99) | 259 | 4 | 5 | n/m | |||||
| Capex | — | — | — | — | (1) | (1) | (2) | 0 | — | — | (24.9%) | ||||||
| Free cash flow | — | — | — | (12) | (99) | (165) | (101) | 259 | 4 | 5 | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | 40 | 271 | 385 | 289 | 577 | 63 | 21 | (10.5%) | |||||
| Net debt | — | — | — | (43) | (254) | (383) | (302) | (567) | (52) | (9) | (22.3%) | ||||||
| Shareholders’ equity | — | — | — | 39 | (98) | 387 | 294 | 581 | 63 | 21 | (10.2%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | (111.09) | (86.40) | (55.64) | (29.56) | 66.19 | 0.73 | 11.63 | +122.7 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (2,990.73) | 0.00 | (450.47) | (217.43) | (7.12) | (7.1) pt | ||||||
| ROE | — | — | — | 32.79 | 245.17 | (135.72) | (32.39) | 70.96 | 0.77 | 11.75 | (21.0) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | 87 | 107 | 163 | — | — | — | +36.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | n/m | ||||||
Negative figures in brackets.
estimates
LianBio Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | |
| GRDX GridAI Technologies Corp. | $33.3M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| NNVC NanoViricides, Inc. | $32.9M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PMN Promis Neurosciences | $32.7M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| INMB INmune Bio, Inc. | $32.6M | — (loss-making) | — (loss-making) | +8.70% (above 0%: growing) | n/m | +55.39% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $34.2M | — | — | +8.70% | — | −11.83% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 19 April 2023
Ownership
Directors and executive officers, together
7.59%
Entities affiliated with Perceptive Advisors
53.71%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement